Abstract: A system and method for effectively performing a transmit power adjustment procedure in a wireless network includes a forward receiver that monitors a wireless forward link for forward data that is transmitted over the wireless forward link by a forward transmitter. The forward transmitter initially transmits the forward data at a minimum power level, and gradually increases the minimum power level to a power level threshold at which the forward receiver first detects the forward data on the forward link. Once the forward receiver and the forward transmitter are successfully coupled over the wireless forward link, the forward transmitter may then transmit forward data at a normal operating power level. The foregoing transmit power adjustment procedure ensures that the forward receiver receives forward data only from the forward transmitter, and prevents other proximate wireless devices from inadvertently intercepting forward data transmitted by the forward receiver.

Abstract: In one embodiment a method and apparatus is provided for a digital camera controlled by a remote computer. The remote computer commands the digital camera as to when to take pictures, how long to pause before taking subsequent pictures, and when to stop taking pictures. The digital camera senses current photographic conditions, which are later requested by the remote computer. Based upon the digital camera's current photographic conditions, the remote computer calculates the appropriate exposure parameters for the digital camera and commands the digital camera to set its exposure parameters accordingly. After a picture is taken, the picture is stored as image data in volatile memory in the digital camera. The image data is then transferred to the remote computer for compression and storage in the remote computer's non-volatile memory. The remote computer subsequently encodes the stored image data into a time-lapse video file.

Abstract: A packetized data receiver establishes at the beginning of receiving each respective stream a buffer length for sending packets to higher levels of a protocol stack in the event that a packet is missed. This can be done by requesting retransmission of the first packet and measuring the actual time delay between request and receipt of the retransmitted packet.

Abstract: An error correction compensating ones or zeros string suppression system and method for use in a digital transmission system is herein disclosed. In digital transmission systems utilizing error control coding (ECC)/forward error correction (FEC) to reduce the number of bit errors in a bit stream, long strings of ones and zeros are easily suppressed by detecting a prohibited length of ones or zeros, and flipping a bit in the string of ones or zeros. This method and system removes the violation of the ones or zeros bit string requirement by flipping a bit in the string, while the receiving side utilizes the error correction capability of the ECC/FEC to correct the inverted bit.

Abstract: A packetized data transmitter notes packet transmission times and the times, if any, of retransmission requests from a receiver. Based on the period between original transmission and retransmission of a dropped packet, the transmitter establishes a packet discard period, essentially a transmitter packet buffer length.

Abstract: A videoconferencing method consistent with certain embodiments involves receiving a video stream via a broadband network connection at a television display to display a remote party's inbound video information. A video stream is transmitted via a wireless cellular telephone's camera to the remote party to provide outbound video information. Inbound audio is received from the remote party via the broadband network connection at the television display and playing the audio using the television display's audio circuits. Outbound audio is transmitted to the remote party via the wireless cellular telephone's audio circuits. This abstract is not to be considered limiting, since other embodiments may deviate from the features described in this abstract.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: An apparatus comprising a plurality of columns bound together, configured to display a single row of pixels scanned out from top to bottom. It also comprises a timing control unit to synchronize between the columns to allow all pixels of a single row to be lit at the same time.

Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.

Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Abstract: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of &bgr; lactam antibiotics against many &bgr;-lactamase producing bacteria.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta.-lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta.-lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta.-lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta. lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clvuligerus. This new compound which is designated clavulanic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta.-lactam antibiotics against many .beta.-lactamase producing bacteria.

Abstract: A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulonic acid has the formula (I): ##STR1## In addition to being a broad spectrum antibiotic of medium potancy, clavulanic acid and its salts and esters have the ability to enhance the effectiveness of .beta. lactam antibiotics against many .beta.-lactamase producing bacteria.